Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.

ABSTRACT:

Background

The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer.

Methods

Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness, KRAS/BRAF, mismatch repair, and Immunoscore (CD3⁺, CD8⁺ T-cell densities). After determining optimal functional form (continuous or categorical) and within Cox models, backward selec

SUBMITTER: Sinicrope FA 

PROVIDER: S-EPMC7236783 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature